AAV-delivered TNF-α inhibitors for the treatment of non-infectious uveitis
Molecular Therapy Advances · 2026-12 · 34 (4) · 201874
DOI: 10.1016/j.omta.2026.201874 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-12. Verfasst von Jessica Gumerson und 15 weiteren Autor:innen. Beteiligte Einrichtung: REGENXBIO Inc., 9804 Medical Center Dr., Rockville, MD 20850, USA. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Non-infectious uveitis (NIU) is a vision-threatening inflammatory disease of the eye, which can require long-term systemic immunosuppression associated with significant side effects. Inhibitors of tumor necrosis factor α (TNF-α) have emerged as effective agents for increasing the time between flares. Here, we demonstrate that adeno-associated viral (AAV) vectors can be used to achieve local and sustained inhibition of TNF-α as a potential therapy for treatment of refractory NIU. Vectorized TNF-α antibody-based inhibitors were evaluated in different formats to compare target affinity, transgene expression levels, and bioactivity. In two different murine disease models, local AAV8-mediated expression of TNF-α inhibitor before disease induction prevented both the onset of inflammation and decline in vision, demonstrated by a reduction in immune cell recruitment to the eye, an improvement in inflammation clinical scores, and preservation of retinal function. In a human iPSC-derived retinal pigment epithelial (RPE) inflammation model, prophylactic transduction with AAV8.anti-TNF-α-single-chain variable fragment (scFv) preserved barrier function and suppressed pro-inflammatory cytokine expression in a dose-dependent manner. AAV8.anti-TNF-α-scFv also demonstrated dose-dependent expression and bioactivity in ocular tissues following intraocular delivery in non-human primates (NHPs). These data show that local AAV-mediated inhibition of TNF-α can suppress inflammation associated with uveitis and support further development of a vectorized therapeutic approach for the treatment of NIU.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- REGENXBIO Inc., 9804 Medical Center Dr., Rockville, MD 20850, USA.
Zitieren
APA
Gumerson, J., Shi, M., Kruse, R., Kim, K. H., Tully, C., Kwok, L., Lee, W. H., Wang, X., Glenn, J., Gardner, L., McDougald, D., Bruder, J., Fiscella, M., Danos, O., Liu, Y., & Lilley, B. N. (2026). AAV-delivered TNF-α inhibitors for the treatment of non-infectious uveitis. Molecular Therapy Advances, 34(4), 201874. https://doi.org/10.1016/j.omta.2026.201874
Vancouver
Gumerson J, Shi M, Kruse R, Kim KH, Tully C, Kwok L, et al. AAV-delivered TNF-α inhibitors for the treatment of non-infectious uveitis. Molecular Therapy Advances. 2026;34(4):201874. doi:10.1016/j.omta.2026.201874
BibTeX
@article{Gumerson2026,
author = {Gumerson, Jessica and Shi, Mi and Kruse, Ryan and Kim, Kwi Hye and Tully, Chris and Kwok, Leo and Lee, Wei-Hua and Wang, Xu and Glenn, Justin and Gardner, Louis and McDougald, Devin and Bruder, Joe and Fiscella, Michele and Danos, Olivier and Liu, Ye and Lilley, Brendan N},
title = {AAV-delivered TNF-α inhibitors for the treatment of non-infectious uveitis},
journal = {Molecular Therapy Advances},
year = {2026},
volume = {34},
number = {4},
pages = {201874},
doi = {10.1016/j.omta.2026.201874}
}
EUVIMED